Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A
Phase 1
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia A
- Interventions
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 4
- Registration Number
- NCT01365520
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom
Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2017-03-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 276
- Registration Number
- NCT01365507
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus
- First Posted Date
- 2011-06-02
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 373
- Registration Number
- NCT01364428
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Renton, Washington, United States
Observational, Safety Study of NovoNorm® (Repaglinide) and Insulin Analogue Combination Therapy in Type 2 Diabetes in Korea
- First Posted Date
- 2011-05-18
- Last Posted Date
- 2014-08-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 120
- Registration Number
- NCT01355718
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in India
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetes
- Interventions
- Other: No treatment given
- First Posted Date
- 2011-05-11
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 12000
- Registration Number
- NCT01351922
- Locations
- 🇮🇳
Novo Nordisk Investigational Site, Bangalore, India
Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 Diabetes
- First Posted Date
- 2011-05-02
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1056
- Registration Number
- NCT01345734
- Locations
- 🇵🇭
Novo Nordisk Investigational Site, Manilla, Philippines
Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2011-04-15
- Last Posted Date
- 2018-02-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1663
- Registration Number
- NCT01336023
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wrexham, United Kingdom
Safety of NNC 0123-0000-0338 in Healthy Subjects
Phase 1
Completed
- Conditions
- DiabetesHealthy
- Interventions
- First Posted Date
- 2011-04-12
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 70
- Registration Number
- NCT01334034
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients
Phase 3
Completed
- Conditions
- Haemophilia BCongenital Bleeding Disorder
- Interventions
- First Posted Date
- 2011-04-11
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 74
- Registration Number
- NCT01333111
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Oxford, United Kingdom
Usability and Tolerability of the Norditropin NordiFlex® Injection Device in Children Never Previously Treated With Growth Hormone
Completed
- Conditions
- Growth Hormone DisorderGrowth Hormone Deficiency in ChildrenGenetic DisorderTurner SyndromeFoetal Growth ProblemChronic Renal InsufficiencyDelivery SystemsSmall for Gestational AgeChronic Kidney Disease
- Interventions
- First Posted Date
- 2011-04-04
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 77
- Registration Number
- NCT01327924
© Copyright 2025. All Rights Reserved by MedPath